Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Cyclosporine is a potent immunosuppressive agent, however, its use is limited by nephrotoxicity. Increased production of the potent vasoconstrictor thromboxane A2 contributes to cyclosporine nephrotoxicity in animal models, but the role of thromboxane in human cyclosporine nephrotoxicity has not been established. We therefore studied cyclosporine-treated renal allograft recipients who had evidence of toxicity manifested by decreased renal function. We measured GFR and PAH clearance (CPAH) before, during, and one week after a 48-hour intravenous infusion of the thromboxane synthase inhibitor CGS 13080. At baseline, the urinary excretion of TXB2 and 2,3-dinor-TXB, was elevated in the study patients compared to healthy subjects. CGS 13080 infusion caused selective and nearly complete inhibition of thromboxane metabolite excretion in all patients. Mean CPAH improved 33% from 223 45 to 298 59 mI/min/m2 (P = 0.055) during infusion, while mean GFR improved 9% from 50.1 3.9 at baseline to 54.6 4.5 mllmin/l .73 m2 (P = 0.111). The effect on GFR occurred primarily in those patients taking calcium channel blockers. The mean increase in GFR in these 5 patients was 10.0 2.8 versus -1.0 2.8 mI/minim2 in the remainder. We conclude that thromboxane synthase inhibitors may be useful in attenuating the nephrotoxic effects of cyclosporine following renal transplantation.
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Cyclosporine is a potent immunosuppressive agent which is extremely effective in suppressing rejection in kidney, liver, pancreas, and bone marrow allografts [1] . Recent studies suggest that cyclosporine may also be useful for the treatment of autoimmune diseases [1] . Unfortunately, the clinical applications of cyclosporine have been limited by the frequent occurrence of nephrotoxicity [2, 3] and especially concern about the potential for chronic irreversible renal injury [41. Animal studies suggest that cyclosporine causes renal vasoconstriction [5] . Although several potential mediators of this effect have been proposed [2, 3] , a number of animal studies suggest that part of the renal vasoconstriction associated with cyclosporine administration may be due to increased produc-© 1992 by the International Society of Nephrology thromboxane metabolites and thromboxane production by the kidney are increased in cyclosporine-treated rats [6] [7] [8] [9] [10] . Furthermore, treatment of these animals with either thromboxane synthase inhibitors [7, 10] or thromboxane receptor antagonists [11, 12] improves renal function. In humans, however, a role for thromboxane in cyclosporine nephrotoxicity has not been demonstrated.
The purpose of this study was to investigate the potential role of thromboxane in human cyclosporine nephrotoxicity. We studied a group of renal allograft recipients who were taking cyclosporine as their primary immunosuppressive therapy. To examine the role of thromboxane as a renal vasoconstrictor in these patients, we evaluated the effects of short term administration of the specific thromboxane synthase inhibitor CGS 13080 on renal function and eicosanoid excretion. The structure of CGS 13080 is shown in Figure 1 . This agent has potency five to six orders of magnitude greater with respect to thromboxane synthase than toward other enzymes involved in the metabolism of arachidonic acid in a variety of in vitro systems including bovine aortic, sheep seminal vesicle, and human platelet preparations (CIBA-GEIGY, unpublished observations). In healthy human subjects, CGS 13080 has a rapid onset of action and a half-life after oral administration of approximately one hour [13] . However, its pharmacokinetics and efficacy have not been previously evaluated in renal allograft recipients.
Our results suggest that urinary excretion of thromboxane metabolites is increased in patients taking cyclosporine and that the renal vasoconstriction caused by cyclosporine in these patients is mediated in part by enhanced production of thromboxane A2.
Methods

Patient selection
Adults who had undergone cadaveric renal transplantation at the Duke University or Durham Veterans Affairs Medical Centers within the previous 20 months were considered for enrollment in the study. To be eligible, patients were required to have been treated with cyclosporine for at least one month, with a stable plasma creatinine level of 1.6 to 3.0 mg/dl. Specific exclusion criteria included: clinical evidence of acute or ongoing allograft rejection; females of childbearing potential; presence of serious systemic disease unrelated to the kidney; occult blood in the stool, thrombocytopenia or history of any disorder associated with bleeding; inability to refrain from the use of non-steroidal anti-inflammatory agents for two weeks prior to and two weeks during the study; and elevated serum liver enzymes. Written informed consent was obtained and the study was approved by the Investigation Review Boards of both participating hospitals.
Maneuver
Enrolled patients were admitted to the Clinical Research Unit (CRU) at Duke University Medical Center. Throughout the study, all medications (including cyclosporine) were continued without a change in dose. While on the CRU, patients received a 4 g sodium diet. Blood pressure was recorded at six hour intervals and more frequently during administration of the investigational drug. Urine was collected during consecutive six-hour periods throughout hospitalization for the measurement of eicosanoids and creatinine. Blood sampling was performed using an 18 or 20 gauge intravenous catheter which had been in place for at least 30 minutes.
On the morning after admission, an intravenous infusion of DSW (the vehicle for CGS 13080) was begun at 40 mI/hr. The following morning renal function was measured as described below. After completion of these baseline clearance studies, an intravenous infusion of CGS 13080 in D5W was begun and increased to a dose of 0.5 mg/kg/hr (40 ml/hr). This dose was chosen to provide maximal inhibition of urinary thromboxane excretion on the basis of a pilot study.
After 42 hours of CGS 13080 infusion, renal function measurements were repeated while the CGS 13080 infusion continued. After a total of 48 hours, CGS 13080 infusion was stopped and blood for CGS 13080 level was sampled at frequent intervals over the next 24 hours for pharmacokinetic analysis. One week later, patients were readmitted to the CRU for repeat measurement of renal function.
Renal function measurements Using standard techniques, the urinary clearance of 1251 iothalamate was measured as an index of GFR [141 and the urinary clearance of p-aminohippurate (CPAH) was determined to estimate renal plasma flow [15] . After a breakfast lacking protein, patients were given 15 mi/kg of water to drink over 60 minutes. Urine was collected by spontaneous voiding and additional water was given to maintain urine flow >3 ml/min. After this urine flow rate was established, a priming dose of PAH (0.05 ml/kg of a 20% stock solution diluted to 50 ml) was given intravenously followed by a continuous infusion of a 0.8% PAH solution at 60 mI/mm. At the time of the PAH priming dose, 0.2 MCi/kg of '251-iothalamate was injected subcutaneously. After an equilibration period of at least 60 minutes, the first clearance period was begun. Each study consisted of three consecutive clearance periods of 30 to 60 minutes. Blood samples were drawn at the beginning and end of each period.
Plasma PAH concentration was determined by a standard chemical assay [14] , and '251-iothalamate concentration measured by gamma counter. Plasma values for each period were calculated as the log mean of the bracketing values at the beginning and end of each period. Clearances were calculated using the standard formula UV/P, with each measurement representing the mean of three periods. The data were normalized for body surface area and expressed as mllmin/1 .73 m2.
Urine eicosanoid measurements
Urinary eicosanoids were measured by gas chromatography and mass spectrometry. Ten ml samples of urine were acidified with 0,4 ml of glacial acetic acid, placed on preconditioned PrepSep-R C-18 columns (Fisher Scientific, Pittsburgh, Pennsylvania, USA), washed with 3 ml of 12% acetonitrile (ACN) and eluted with 2 ml of ACN. The samples were dried and redissolved in 1.25 ml of phosphate buffered saline (PBS) containing 0.05 M KH,P04 and 0.15 M NaCI (pH 7.4).
Samples were loaded onto columns containing a mixture of three immunoaffinity resins with selectivity for TXB2/2,3-dinor-TXB2 and 6-keto-PGF1/2,3-dinor-6-keto-PGF1, (provided by Dr. Daniel R. Knapp, Medical University of South Carolina, Charleston, South Carolina, USA) and allowed to equilibrate for 15 minutes. The samples were washed twice with 5 ml of PBS and twice with 5 ml water, eluted with 4 ml of 95% ACN and dried.
Derivatives of the eicosanoids were made using 50 .d 5% diisopropylethylamine in ACN and SO d 25% pentafluorobenzyl bromide in ACN at 60°C for 10 minutes. Derivatives were then made using 50 td of 2% methoxyamine HCI in pyridine at 60°C for one hour and redried. After dissolution in 1 ml of methylene chloride, samples were loaded onto preconditioned B&J Solid Phase System silica columns (Baxter Healthcare
Corp., Muskegon, Michigan, USA), washed with 2 ml of 1.5% methanol in methylene chloride (vol/vol) eluted with 1 ml of 5% methanol in methylene chloride and dried. Derivatives were made using 50 d of N,O,-bis-(trimethylsilyl)trifluoroacetamide containing 1% trimethylsilylchlorosilane at 60°C for 60 minutes and redried.
Residues were dissolved in 25 .&d of n-dodecane and measured by stable isotope-dilution assays by means of selective-ion monitoring of the ratio of the compound to the m/z ion of the deuterium labelled internal standard. Gas chromatography was performed on a DB-17 fused silica column ( Data are presented as means SD (minimum, maximum).
mm, to 276°C at 4.4°C/mm and held for three minutes. Eicosanoids were detected by negative chemical ionization mass spectrometry using methane as the reagent gas. TXB2 and 6-keto-PGF1 were quantified by measuring the ratio of the intensity of ions m/z 614/618; for 2,3-dinor-TXB, and 2,3-dinor-PGF1,, m/z 586/590. Urinary eicosanoid concentrations were determined by extrapolation from standard curves generated for each eicosanoid and expressed as pg/mg creatinine (Cr). Twelve hour urine collections were made by 34 healthy males (taking no medication) to establish reference ranges for eicosanoid excretion as determined by these assays.
Serum TXB2
Serum TXB2 was determined by radioimmunoassay. Samples were collected in glass tubes with no additives, incubated at 37°C for one hour and centrifuged. Unlabelled TXB2 (Upjohn Co., Kalamazoo, Michigan, USA) was dissolved in 10% ACN. Dilutions of serum samples and TXB2 standards ranging from 0.072 to 18 ng/ml were made in a buffer containing 0.5 M Tris-HC1 (pH 6.8), 0.9% NaCI, 0.3% bovine serum albumin, 0.05% NaN3 and 0.01 54 EDTA. Samples were assayed in duplicate. The '251-methyl ester of TXB2 (Advanced Magnetics, Cambridge, Massachusetts, USA) was added to all sample and standard tubes. Rabbit antiserum to TXB2 (Advanced Magnetics) was then added and the tubes were incubated for 16 hours at 4°C. An excess of goat anti-rabbit antibody bound to paramagnetic particles was then added. The antibody/antigen complexes were separated using a magnetic rack (Ciba-Corning Diagnostics, Walpole, Massachusetts, USA) and washed once. Bound radioactivity was determined by gamma counter and serum TXB2 levels determined by comparison with a standard curve using four parameter logistic curve fitting.
Plasma CGS 13080 Blood samples for assay of CGS 13080 level were collected in tubes containing lithium heparin and the plasma level determined by fluorometric detection after HPLC separation. Plasma concentrations are expressed as ng/ml plasma.
Whole blood cyclosporine Trough whole blood cyclosporine levels were determined by a standard HPLC assay that is insensitive to levels below 50 ng/ml [161. For purposes of analysis, levels below this threshold were considered to be 50 ng/ml.
Statistical analysis
Means are presented as the mean standard error of the mean (sEM) except where noted. This study had 80% power to detect an 18% change in GFR during treatment with CGS 13080 with a 5% chance of making Type I error. Hypothesis testing for the primary outcomes of interest (GFR, CPAH, eicosanoid levels) was performed using the paired f-test, after confirming that the data approximated a normal distribution using the Shapiro-Wilk test. An ambiguity in the recording of clearance period times during the study drug infusion in one patient made calculation of renal function parameters impossible in that case. All other data from this patient are included in the analysis.
Results
Eleven male patients were studied. The etiology of end-stage renal disease was hypertension in three patients, diabetes mellitus, membranoproliferative glomerulonephritis and IgA nephropathy in one patient each, and unknown in the remaining five. Baseline characteristics of the study patients are shown in Table 1 . Figure 2 shows urinary eicosanoid excretion for study patients during the baseline period compared with that of 34 healthy males. Urinary excretion of native, unmetabolized TXB2 was significantly higher (P = 0.004) in cyclosporinetreated renal allograft recipients (60 5 pg TXB2/mg Cr) than in the controls (35 6) . Likewise, excretion of 2,3-dinor-TXB2 was elevated (P = 0.025) in study patients (534 90 pg/mg Cr) compared to controls (291 33). In contrast, the serum TXB2 levels were lower (P = 0.002) in patients at baseline (263 53 ng/ml) than in 12 healthy subjects (351 34). There were no significant differences in the excretion of prostacyclin metabolites between the study patients and healthy subjects. Figure 3 shows mean urinary eicosanoid excretion before, during, and immediately after the 48 hour infusion of CGS 13080. As seen in panels A and B, CGS 13080 rapidly and effectively inhibited excretion of TXB2 and 2,3-dinor-TXB2 in all patients. Excretion of thromboxane metabolites remained suppressed until the infusion of CGS 13080 was stopped. Over the 18 hours of study after the infusion was stopped, excretion of thromboxane metabolites increased toward, but did not reach pre-infusion levels. There was no apparent effect of CGS 13080 infusion on excretion of prostacyclin metabolites, as shown in panels C and D of Figure 3 .
Blood pressure and heart rate were stable throughout the study protocol (Fig. 4) with no apparent change induced by the study drug. Likewise, plasma cyclosporine levels were unaffected by CGS 13080 (Table 2) . Mean CGS 13080 level at steady state was 1891 ng/ml, while the terminal half-time for the 
Subgroup analysis showed that the effect on GFR occurred
Time, hours primarily in those patients who were taking a calcium channel blocker as part of their antihypertensive regimen (indicated by closed circles in Fig. 5 ). The mean increase in GFR during CGS 13080 infusion among the five patients taking calcium channel blockers was 10.0 2.8 ml/min/1.73 m2 versus -1.0 2.4 for the remainder. CPAH increased by a mean of 90 60 mi/minI 1.73 m2 in the calcium channel blocker group versus 59 37 in disappearance of the drug from plasma averaged 73.1 minutes. At 24 hours after the infusion was stopped, CGS 13080 was detectable in the plasma of only one patient. Table 2 shows the renal function measurements before, during and one week after CGS 13080 infusion, as well as the corresponding eicosanoid data. CPAH increased by a mean of 33% during infusion of CGS 13080 compared to baseline (P = 0.055). As shown in Figure 5A , renal plasma flow improved in 8 of 10 patients during CGS 13080 treatment. There was not a significant correlation between the changes in CPAH or GFR and the percent inhibition of excretion of either TXB2 or its dinor metabolite.
patients not taking calcium blockers.
Despite the short half-life of CGS 13080, serum TXB2 and urinary thromboxane metabolite excretion were still significantly suppressed one week after the drug was discontinued (Table 2 ). In addition, the trend for improved renal function persisted at one week post-drug for both mean GFR (P 0.090) and CPAH (P = 0.061) compared to baseline.
Discussion
The arachidonic acid metabolite thromboxane A3 has several biologic actions which may contribute to the pathogenesis of renal disease. In the kidney, thromboxane causes renal vasoconstriction [17] and contraction of mesangial cells [18] . In addition, platelet aggregation and release functions are stimulated by thromboxane [19] and may play a role in promoting glomerular cell proliferation in immune-mediated renal disease [20] . Previous studies have suggested that enhanced production of thromboxane may have a pathogenetic role in a number of kidney diseases including: (1) ureteral obstruction [21, 22] ; (2) lupus nephritis [23, 24] ; (3) renal allograft rejection [25] [26] [27] ; (4) experimental glomerulonephritis [28, 29] ; (5) diabetic nephropathy [30] ; and (6) cyclosporine toxicity [6] [7] [8] [9] [10] [11] [12] . Thus thromboxane A2 appears to be a part of a final common pathway for renal injury in diseases of diverse etiology.
In the present study, urinary excretion of thromboxane metabolites was elevated in cyclosporine-treated patients compared to healthy controls. The significant increases in excretion of both TXB2 and 2,3-dinor-TXB2 in the patient group were very similar to our previous observations in rats given large doses of cyclosporine [10] . Current evidence suggests that native, unmetabolized TXB2 in urine reflects thromboxane production by the kidney, while 2,3-dinor-TXB2 may primarily reflect systemic thromboxane production [31, 32] . It is conceivable that some portion of the increase in 2,3-dinor-TXB2 excretion in our patients might be attributable to elevated platelet thromboxane production, since Jorkasky et al [33] have previously reported increased production of thromboxane by platelets exposed to cyclosporine. However, serum TXB2 levels, which are a direct measure of platelet thromboxane production, were actually lower in the patients we studied compared to normal. This suggests that the increased 2,3-dinor-TXB2 in our cyclosporine-treated patients might have derived from non-platelet sources. We cannot rule out the possibility that the native kidneys were in part responsible for the increase in thromboxane metabolite excretion seen in our cyclosporinetreated patients.
The marked decreases in urinary TXB2 and 2,3-dinor-TXB2 excretion and the reduction in serum TXB2 levels during infusion of CGS 13080 reflect selective and nearly complete inhibition of renal and systemic thromboxane production. It has been suggested that the beneficial physiologic effects of selective thromboxane synthase inhibition may be due in part to shunting of endoperoxides toward the synthesis of vasodilator prostanoids [34] . In the present study, however, no increase in prostacyclin metabolite excretion was observed during CGS 13080 infusion. Since cyclosporine levels and blood pressure also did not change during the infusion, the observed improvement in renal function can be attributed to the direct effects of inhibition of thromboxane. Although the molecular mechanism and reversibility of thromboxane synthase inhibition induced by CGS 13080 are unclear, its effects on thromboxane production persisted long after the drug had been cleared from plasma. For up to one week after the infusion discontinued, both serum TXB2 levels and urinary excretion of thromboxane metabolites were reduced. In addition, one week after the infusion was stopped CPAH and GFR remained numerically higher than at baseline.
There are a number of potential causes of renal dysfunction in the first twelve months following transplantation [35] . To reduce the chance that patients in the study might have renal insufficiency related to rejection or causes other than cyclosporifle nephrotoxicity, we selected patients with mild, yet stable levels of renal dysfunction. By selecting only patients with modest functional impairment, we may have excluded those patients who would have benefitted most from the intervention.
Nevertheless, eight of the ten patients studied experienced improvements in PAH clearance over the relatively short period of drug administration. This observation is in accord with a recent report by van der Heide et al [36] showing improvement in renal function in cyclosporine-treated renal allograft recipients given dietary fish oil supplements, which reduce renal thromboxane production [37] . In a study by Zipser [38] , thromboxane synthase inhibition did not affect inulin and PAH clearance in healthy subjects. In addition, CGS 13080 has been given to more than 75 subjects not taking cyclosporine without any discernible effect on the serum creatinine (CIBA-GEIGY, unpublished observations).
Although our data provide suggestive evidence that acute infusions of CGS 13080 may ameliorate cyclosporine nephrotoxicity, thromboxane inhibitors may have other beneficial effects following renal transplantation. Our group and others have shown that thromboxane inhibition improves the course of allograft rejection in animal models [25, 27, 39, 40] . In our experience in these animal models [25, 40] , the effects of long-term treatment with thromboxane inhibitors are generally greater than the effect of acute administration protocols such as that utilized in this study. This current study clearly documents the feasibility of attaining specific inhibition of thromboxane synthesis in renal allograft recipients, and we are actively evaluating the effects of prolonged administration of thromboxane synthase inhibitors on transplant function.
The beneficial effect of CGS 13080 on GFR was most marked in patients who were also taking calcium channel blockers. Four of the five patients taking calcium channel blockers experienced increases in GFR of a magnitude which would be considered clinically significant. This is of interest in light of previous reports that have demonstrated synergistic effects of thromboxane synthase inhibitors and calcium channel blockers on inhibition of platelet aggregation and platelet thromboxane production [41, 42] . In addition, Loutzenhiser et al [43] were able to block the effect of the thromboxane agonist U-44069 on rat aortic rings and isolated perfused kidneys by pretreating with diltiazem. Previous studies have suggested that pretreatment with calcium channel blockers alone may protect against cyclosporine nephrotoxicity [44] . Although the mechanism of this effect is unclear, proposed explanations include direct vasodilatation, protection of cell membranes from calcium dependent phospholipid breakdown, and inhibition of intracellular calcium accumulation [441. As GFR was improved more than CPAH in patients in the present study who were taking calcium channel blockers, it may be that the combined effect of CGS 13080 and calcium channel blockade is to increase Kf by inhibiting thromboxane-induced mesangial cell contraction. In any event, our results suggest that the beneficial effects of calcium channel blockers in cyclosporine nephrotoxicity may relate to their antagonistic effects on the synthesis or actions of thromboxane A2. The two most common clinical syndromes of cyclosporine nephrotoxicity can be broadly divided into acute reversible renal vasoconstriction and chronic irreversible nephropathy [2, 3] . Acute cyclosporine nephrotoxicity is characterized by a reversible increase in renal vascular resistance associated with reductions in both renal blood flow and glomerular filtration rate. Generally, this acute syndrome is non-progressive, dosedependent and reverses with dose reduction or discontinuation of the drug. Chronic cyclosporine nephropathy is defined by the development of interstitial fibrosis and irreversible reduction in renal function. Morphologically, chronic cyclosporine nephropathy is characterized by focal or striped interstitial fibrosis with tubular atrophy. Often these changes are accompanied by obliterative arteriolar lesions. In some patients, this renal fibrosis and loss of kidney function may be progressive [1] [2] [3] [4] . In addition to the vasoconstrictive properties of thromboxane, recent studies have shown that thromboxane agonists can stimulate the production of extracellular matrix proteins by mesangial cells [45] . Thus, an enhancement of renal thromboxane production by cyclosporine may promote the abnormal accumulation of matrix proteins in the kidney. Therefore, thromboxane may be involved in the pathogenesis of both the acute vasoconstriction as well as the chronic renal injury associated with cyclosporine nephrotoxicity. Moreover, it is possible that long term administration of thromboxane inhibitors may help prevent the development of renal fibrosis, which is the most clinically important manifestation of cyclosporine nephrotoxicity.
In summary, the results of this study suggest that renal thromboxane production is enhanced in renal allograft recipients treated with cyclosporine. Administration of CGS 13080 caused nearly complete inhibition of renal and systemic thromboxane production. In this patient group, thromboxane synthase inhibition tended to improve renal function, particularly in patients taking calcium channel blockers. We conclude that thromboxane synthase inhibitors may be useful in ameliorating the nephrotoxic effects of cyclosporine following renal transplantation.
